Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

Key facts

Sponsor

University of Southern California

Principal Investigator

Sarmad Sadeghi

University of Southern California

Intervention

Anti-OX40 Antibody PF-04518600(biological)

Enrollment

62 enrolled

Eligibility

18 years · All sexes

Timeline

2017 – 2026

Study locations (10)

• Los Angeles County-USC Medical Center, Los Angeles, California, United States
• USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
• USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
• University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
• University of Kansas Cancer Center, Kansas City, Kansas, United States
• Weill Cornell Medical College, New York- Presbyterian Hospital, New York, New York, United States
• Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
• Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
• University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
• University of Virginia Cancer Center, Charlottesville, Virginia, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Clear cell renal carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07128680
  Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
  City of Hope Medical Center
• RECRUITINGPHASE2NCT06863311
  Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
  Karie Runcie
• RECRUITINGPHASE2NCT07397611
  Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
  Dana-Farber Cancer Institute
• RECRUITINGPHASE2NCT07469683
  An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
  Yonsei University
• RECRUITINGPHASE2NCT07188896
  A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
  Brian Rini
• RECRUITINGPHASE1, PHASE2NCT07227415
  A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
  Pfizer
• RECRUITINGPHASE1, PHASE2NCT07551349
  Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
  Beijing Biotech
• RECRUITINGPHASE2NCT07223541
  Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
  University of Oklahoma

See all trials for Clear cell renal carcinoma →